The companies that started New York's legal cannabis industry are asking the state for relief. MJBizDaily reported in June that New York's vertically integrated medical operators, known as registered organizations (ROs), owe up to $15 million each in fees tied to their entry into the adult-use market. The operators say they can't pay at today's prices. Adult-use businesses say the money was promised and should be collected. Here is what is owed, why, and what has changed since.

Update: October 2026

As of October 9, the state has not cut the multimillion-dollar adult-use fee. OCM's releases for the August 6 and September 3 board meetings list no action on it, and we found no reported court ruling in the operators' lawsuit. A few things did change around the medical companies:

The next chances for change are monthly Cannabis Control Board meetings, any ruling on the lawsuit, and the governor's executive budget in January 2027.

Advertisement

Two different fees, two different stories

Coverage often lumps together two separate charges:

  1. The medical registration fee. This is a recurring fee set in state regulation (9 NYCRR 113.7(c)) for holding an RO registration. On May 29, 2026, days before this story first ran, the board cut it from $200,000 to $20,000 (Resolution No. 2026-39). The resolution says the number of certified patients and medical sales "have declined over the past several years with the increased size of the adult-use cannabis program."
  2. The adult-use special licensing fee. This is a one-time payment ROs owe to sell to adult-use customers. Regulators first set it at $20 million, payable in installments with $5 million due up front, according to Benzinga's report on the industry lawsuit. Trade coverage says it was later lowered to $15 million. That fee is what operators say they can't afford.

The May cut saves each operator $180,000 per registration period, which is small next to the adult-use fee.

How the medical pioneers got here

The Compassionate Care Act of 2014 created the RO model: a small number of companies licensed to grow, process and sell medical cannabis under strict rules. They paid for infrastructure for years before the 2021 Marijuana Regulation and Taxation Act (MRTA) created a much bigger adult-use market.

That market drew patients away. Ganjapreneur, citing state data, reported 92,967 registered patients and 39 medical-only dispensaries on May 1, 2025, and OCM's count is about 24,000 lower now. MJBizDaily reported that three of the original 10 ROs have gone out of business. In 2025, a lawyer for the New York Medical Cannabis Industry Association (NYMCIA) told Spectrum News the industry expected to rebuild the medical market almost from scratch.

The equity math behind the fee

The adult-use fee was supposed to help pay for New York's social and economic equity program. MJBizDaily reported it was meant to go toward a $200 million fund officials promised for small operators' startup costs. Adult-use licensees, many of them equity businesses that were short on capital, argue that cutting the fee now would shift costs onto them.

The ROs have fought back in court and in the Legislature:

  • Lawsuit. NYMCIA sued the board and OCM in December 2024. It argued the fee is effectively a tax that only the Legislature can impose, and that it violates the MRTA and the state Constitution. Benzinga reported that only four of the 10 original ROs had paid the first $5 million installment when the suit was filed.
  • Legislation. Assembly Bill A7646, with a Senate companion S3151, would change the payment schedule to $5 million at licensure, then $1 million for every $20 million in revenue, with any unpaid balance expiring at the end of 2032. It was sent back to committee in January 2026 and has not passed.

What it means for patients

Most patients won't notice a fee dispute, but they would notice its effects. Struggling operators cut dispensary hours, close locations and carry fewer specialized products such as tinctures and measured-dose formats that adult-use stores don't always stock. The state has spent a year trying to make the medical program more appealing: Hochul's S3294A extended certifications and opened the door to out-of-state patients. That effort depends on companies still being in business to serve patients.

What to watch

  • Whether the board or the Legislature changes the adult-use fee or its payment schedule.
  • A ruling on NYMCIA's lawsuit.
  • Whether the patient count stabilizes now that the July rules are in force.
  • How federal Schedule III status and DEA oversight affect RO costs.

For adults 21+ and certified medical patients.